This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new clinical study has shown that supplements of a lactic acid bacterium may have positive effects by increasing the diversity of intestinal bacteria in these infants. Extremely preterm infants can suffer from a life-threatening inflammation of the gut.
Additionally, it will work on non-clinical toxicity (TOX) and Clinical Trial Material batch to conduct a Phase I clinical trial of the vaccine in healthy adult subjects. This trial will evaluate the safety of the vaccine and generate efficacy data. A sexually transmitted disease, gonorrhoea is caused by the NG bacteria.
An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. Pivotal trials on LMN-201 are expected to commence in 2023. It is compatible with standard-of-care antibiotics.
Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.
The company says that these four serotypes represent roughly 10–15% of bacteria causing pneumococcal disease in adults. Pneumococcal vaccines are used to inoculate individuals against infections caused by the Streptococcus pneumoniae bacteria. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.
Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.
diff – a bacterium that causes diarrhoea and inflammation in the colon and is a major cause of illness and death worldwide – as well as other targets like inflammatory bowel disease. diff coming through clinical trials, some of which also have deep-pocketed partners. billion, but only included markets outside North America.
Anthrax is a rare, yet severe disease caused by the bacterium B. The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Moreover, the clinical trials demonstrated that Cyfendus exhibited a favorable tolerability profile. What Is Anthrax?
Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.
To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments). The antihistamine treatment is currently being evaluated in larger clinical trials.
Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.?
This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. 2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. billion in 2022. billion ($1.17
As of November, the WHO has discouraged the use of the drug as the agency’s review of data from four different clinical trials yielded no worthy effect on mortality, need for mechanical ventilation, time to clinical improvement or any other important patient outcomes. CRISPR Therapeutics.
This theme addresses antimicrobial resistance (AMR), a critical issue where bacteria, viruses, fungi and parasites develop resistance to treatments, making infections harder — or sometimes impossible — to treat effectively. Companies like Merck and Entasis are advancing treatments like ETX0282C, which shows potential in Phase III trials.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content